Clin Chem:平衡血管紧张素II在原发性醛固酮增多症诊断中的应用

2020-04-05 MedSci原创 MedSci原创

在筛选原发性醛固酮增多症(PA)时,许多药物(包括大多数抗高血压药物)和生理因素会影响醛固酮/肾素比率(ARR)。

在筛选原发性醛固酮增多症(PA)时,许多药物(包括大多数抗高血压药物)和生理因素会影响醛固酮/肾素比率(ARR)。本研究试图验证一种新的平衡血管紧张素II (eqAngII)检测方法,并比较在肾素-血管紧张素系统受影响的条件下,醛固酮/血管紧张素II比值(AA2R)与当前ARR之间的相关性。

研究纳入的78例患者,其中有22例经PA排除,56例经氟氢化可的松抑制试验(FST)证实为患者。检测外周血eqAngII、血浆肾素活性(PRA)和直接肾素浓度(DRC)。

研究结果显示,EqAngII与DRC和PRA的一致性良好,与PA的诊断、姿势和氟氯可的松的使用无关。EqAngII在FST时与DRC (r = 0.691)和PRA (r = 0.754)有密切(P < 0.01)的相关性。在312个样本中,DRC和PRA的功能灵敏度分别低于43.9%和15.1%,而eqAngII的灵敏度仅为7.4% (P < 0.01)。Bland-Altman分析显示,在低肾素水平的样本子集中,与eqAngII相比,PRA和DRC被高估了。无论是通过DRC(r = 0.878)还是PRA(r = 0.880)测量肾素,AA2R不仅显示出与ARR一致的变化,而且与ARR密切相关(P <0.01)。

研究结果表明,eqAngII和AA2R的动态变化与肾素和ARR具有良好的一致性和密切的相关性。eqAngII法比DRC和PRA法有更好的敏感性,特别是在低浓度下。AA2R是否能降低一些影响ARR诊断能力的因素的影响,值得进一步研究。

原始出处:

Zeng Guo, Marko Poglitsch,Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080075, encodeId=bcc020800e597, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 27 10:01:53 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846874, encodeId=bc1f18468e42d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Aug 20 14:01:53 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379246, encodeId=aec013e9246b4, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506869, encodeId=7d39150686967, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589335, encodeId=8c5f1589335d0, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080075, encodeId=bcc020800e597, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 27 10:01:53 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846874, encodeId=bc1f18468e42d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Aug 20 14:01:53 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379246, encodeId=aec013e9246b4, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506869, encodeId=7d39150686967, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589335, encodeId=8c5f1589335d0, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080075, encodeId=bcc020800e597, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 27 10:01:53 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846874, encodeId=bc1f18468e42d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Aug 20 14:01:53 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379246, encodeId=aec013e9246b4, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506869, encodeId=7d39150686967, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589335, encodeId=8c5f1589335d0, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
    2020-04-07 cmsvly
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080075, encodeId=bcc020800e597, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 27 10:01:53 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846874, encodeId=bc1f18468e42d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Aug 20 14:01:53 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379246, encodeId=aec013e9246b4, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506869, encodeId=7d39150686967, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589335, encodeId=8c5f1589335d0, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2080075, encodeId=bcc020800e597, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 27 10:01:53 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846874, encodeId=bc1f18468e42d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Aug 20 14:01:53 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379246, encodeId=aec013e9246b4, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506869, encodeId=7d39150686967, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589335, encodeId=8c5f1589335d0, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Tue Apr 07 04:01:53 CST 2020, time=2020-04-07, status=1, ipAttribution=)]

相关资讯

ESC2009肺高血压诊断治疗指南

ESC2009肺高血压诊断治疗指南.doc

难治性高血压诊断治疗中国专家共识

  由北京大学人民医院孙宁玲教授、北京大学第一医院霍勇教授、上海市高血压研究所王继光教授等国内知名专家制定的《难治性高血压诊断治疗中国专家共识》(以下简称共识)近日发表于2013年第4期《中华高血压杂志》上。   共识指出难治性高血压(RH)的定义为,在改善生活方式的基础上,应用了合理可耐受的足量≥3种降压药物(包括利尿剂)治疗>1月血压仍未达标,或服用≥4种降压药物血压才能有效控制。目前RH患

2012中国“骨髓增生异常综合征诊疗共识”发布(附下载)

       骨髓增生异常综合征( MDS)是起源于造血干细胞的一组异质性髓系克隆性疾病,特点是髓系细胞发育异常,表现为无效造血、难治性血细胞减少、造血功能衰竭,高风险向急性髓系白血病(AML)转化。为规范临床诊治,中华医学会血液分会组织相关专家,讨论完成2012年《骨髓增生异常综合征诊断与治疗专家共识》,该共识发表在最新一期的《中华血液学杂志》上。 &n

Hepatology:厦门大学生科院发现肝癌诊断治疗新靶点

厦门大学生命科学学院等处的研究人员首次阐明了YAP-TEAD通过调节HNF4α控制肝癌发生的分子机制,并通过给肝癌重新表达HNF4α可以完全抑制YAP-TEAD信号过度激活引发的肝细胞过度增殖,从而为肝癌的诊断和治疗提供了新的靶点。